NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Price, News & Analysis $44.05 -1.49 (-3.27%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$43.70 -0.34 (-0.78%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Spruce Biosciences Stock (NASDAQ:SPRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spruce Biosciences alerts:Sign Up Key Stats Today's Range$42.80▼$45.0450-Day Range$42.78▼$63.4052-Week Range$40.33▼$199.20Volume83,764 shsAverage Volume89,722 shsMarket Capitalization$126.42 millionP/E RatioN/ADividend YieldN/APrice Target$158.33Consensus RatingModerate Buy Company Overview Spruce Biosciences, Inc. is a biotechnology company focused on developing medicines for rare endocrine disorders. The company’s research centers on conditions in which abnormal hormone production creates significant health complications and limited treatment options. Spruce’s lead product candidate is tildacerfont, an investigational, orally administered selective corticotropin-releasing factor type 1 receptor antagonist. The therapy is designed to regulate the hypothalamic-pituitary-adrenal axis and reduce excessive adrenocorticotropic hormone and adrenal androgen production. Spruce has studied tildacerfont primarily in congenital adrenal hyperplasia, a rare inherited disorder that affects the adrenal glands, and has evaluated its potential in other endocrine-related conditions. Spruce Biosciences has operated as a clinical-stage company serving the global biopharmaceutical and rare-disease markets. Its development programs have focused on advancing targeted treatments through clinical testing and regulatory evaluation rather than commercializing an established portfolio of products.AI Generated. May Contain Errors. Read More Spruce Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSPRB MarketRank™: Spruce Biosciences scored higher than 57% of companies evaluated by MarketBeat, and ranked 325th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSpruce Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSpruce Biosciences has a consensus price target of $158.33, representing about 259.4% upside from its current price of $44.05.Amount of Analyst CoverageSpruce Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spruce Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Spruce Biosciences are expected to grow in the coming year, from ($25.53) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Spruce Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.69% of the float of Spruce Biosciences has been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 4.53.Change versus previous monthShort interest in Spruce Biosciences has recently increased by 3.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.88 News SentimentSpruce Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Spruce Biosciences this week, compared to 3 articles on an average week.Search Interest3 people have searched for SPRB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.30% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spruce Biosciences' insider trading history. Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRB Stock News HeadlinesSpruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual MeetingOctober 8 at 4:31 PM | financialpost.comFHead to Head Review: Spruce Biosciences (NASDAQ:SPRB) versus Vertex Pharmaceuticals (NASDAQ:VRTX)October 7, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)Analysts Are Bullish on These Healthcare Stocks: Spruce Biosciences (SPRB), Arcus Biosciences (RCUS)October 3, 2026 | theglobeandmail.comLake Street initiates coverage of Spruce Biosciences at buySeptember 18, 2026 | msn.comSpruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | businesswire.comOppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)August 28, 2026 | theglobeandmail.comSpruce Biosciences stock gains after analyst backs regulatory progressAugust 27, 2026 | finance.yahoo.comSee More Headlines SPRB Stock Analysis - Frequently Asked Questions How have SPRB shares performed this year? Spruce Biosciences' stock was trading at $87.11 on January 1st, 2026. Since then, SPRB shares have decreased by 49.4% and is now trading at $44.05. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($6.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.79) by $0.89. When did Spruce Biosciences' stock split? Shares of Spruce Biosciences reverse split before market open on Monday, August 4th 2025.The 1-75 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Spruce Biosciences IPO? Spruce Biosciences (SPRB) raised $90 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spruce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE), Meta Platforms (META) and Disc Medicine (IRON). Company Calendar Last Earnings8/12/2026Today10/10/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, SPRB's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SPRB CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees8Year Founded2016Price Target and Rating Average Price Target for Spruce Biosciences$158.33 High Price Target$283.00 Low Price Target$104.00 Potential Upside/Downside+259.4%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($39.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-123.53% Return on Assets-90.35% Debt Debt-to-Equity Ratio0.05 Current Ratio9.23 Quick Ratio9.23 Sales & Book Value Annual Sales$4.91 million Price / Sales25.75 Cash FlowN/A Price / Cash FlowN/A Book Value$39.72 per share Price / Book1.11Miscellaneous Outstanding Shares2,870,000Free Float2,750,000Market Cap$126.42 million OptionableOptionable Beta3.25 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:SPRB) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
